Ipsen makes up to $1.75B blood cancer bet with Kartos buyout
The star of Ipsen’s acquisition is an MDM2 blocker being proposed as an add-on therapy to ruxolitinib for myelofibrosis. The drug could be available to patients “as early as 2028,” according to Ipsen CEO David Loew.
Ipsen makes up to $1.75B blood cancer bet with Kartos buyout Read More »
